Interview with John Chalmers, Senior Director, The George Institute
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston to work at MIT…
Address: Level 13, 321 Kent Street, Sydney,Australia
Tel: +61 2 9657 0300
Web: http://www.georgeinstitute.org.au/
The George Institute conducts research that shapes global health. Our research takes place across a broad health landscape, underpinned by a desire to have the highest impact on healthcare for disadvantaged populations across all corners of the world. Since 1999, our work has seen countless discoveries that have shaped global health plans, decisions and outcomes for millions of people.
Over the last decade, the Institute has delivered high-impact evidence from a large program of research and innovation that has influenced health policy and healthcare practice worldwide.
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston to work at MIT…
Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its research activities? Broadly speaking,…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
See our Cookie Privacy Policy Here
